Cost-effectiveness model of trastuzumab deruxtecan as second-line treatment in HER2-positive unresectable and/or metastatic breast cancer in Finland.
Jeroen H J PaulissenAhmed H SeddikKyle J DuntonChristopher J LivingsMarinus H van HulstMaarten Jacobus PostmaLisa Aniek de JongRoel D FreriksPublished in: The European journal of health economics : HEPAC : health economics in prevention and care (2023)
T-DXd is cost-effective based on surrogate WTP thresholds of €72,000 and €139,000 per QALY.